Pain‐free response at 2 h for moderate to severe baseline pain · adults with migraine headache ‐ moderate or severe and mild baseline pain
1 finding from 1 review
no estimate extracted
Studies not reported
High
Headache relief at 2 h for moderate to severe baseline pain · adults with migraine headache ‐ moderate or severe and mild baseline pain
1 finding from 1 review
no estimate extracted
Studies not reported
High
Sustained pain‐free during the 24 h post dose for moderate to severe baseline pain · adults with migraine headache ‐ moderate or severe and mild baseline pain
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Sustained headache relief during the 24 h post dose for moderate or severe baseline pain · adults with migraine headache ‐ moderate or severe and mild baseline pain
1 finding from 1 review
no estimate extracted
Studies not reported
High
At least 1 AE during treatment for moderate to severe baseline pain · adults with migraine headache ‐ moderate or severe and mild baseline pain
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Use of ECMO before hospital discharge · respiratory failure in infants born at or near term
Inhaled NO at moderate showed no clear difference in use of ECMO before hospital discharge compared with severe criteria (moderate certainty).
1 finding from 1 review
Progression to severe criteria · respiratory failure in infants born at or near term
Inhaled NO at moderate probably leads to lower progression to severe criteria compared with severe criteria (moderate certainty).
1 finding from 1 review
Neurodevelopmental disability at 18 to 24 months among survivors · respiratory failure in infants born at or near term
Inhaled NO at moderate showed no clear difference in neurodevelopmental disability at 18 to 24 months among survivors compared with severe criteria (moderate certainty).
1 finding from 1 review
Death or requirement for ECMO · respiratory failure in infants born at or near term
Inhaled NO at moderate showed no clear difference in death or requirement for ECMO compared with severe criteria (low certainty).
1 finding from 1 review
Mortality before hospital discharge · respiratory failure in infants born at or near term
Inhaled NO at moderate showed no clear difference in death before hospital discharge compared with severe criteria (moderate certainty).
1 finding from 1 review
Low birthweight · pregnant women
Mild/moderate topical corticosteroids may leads to lower low birth weight compared with no topical corticosteroids (low certainty).
1 finding from 1 review
RR 0.9
55713 participants
Low
Preterm birth · pregnant women
Mild/moderate topical corticosteroids may leads to lower preterm delivery compared with no topical corticosteroids (low certainty).
1 finding from 1 review
RR 0.88
55713 participants
Low
Foetal death · pregnant women
Mild/moderate topical corticosteroids may leads to lower foetal death compared with no topical corticosteroids (low certainty).
1 finding from 1 review
RR 0.7
48749 participants
Low
Low Apgar score · pregnant women
Mild/moderate topical corticosteroids may leads to lower low Apgar score compared with no topical corticosteroids (low certainty).
1 finding from 1 review
RR 0.73
8756 participants
Low
Congenital abnormality · pregnant women
Mild/moderate topical corticosteroids may leads to lower congenital abnormality compared with no topical corticosteroids (low certainty).
1 finding from 1 review
RR 0.93
9263 participants
Low
Orofacial cleft · pregnant women
Mild/moderate topical corticosteroids may leads to lower orofacial cleft compared with no topical corticosteroids (low certainty).
1 finding from 1 review
RR 0.95
38446 participants
Low
Moderate to vigorous physical activity (minutes/d) [ · adults
1 finding from 1 review
Moderate‐to‐severe exacerbations (rate) · stable COPD
Triple therapy may leads to lower moderate‐to‐severe exacerbations (rate) compared with LABA/LAMA combination (low certainty).
1 finding from 1 review
Major neurological disability at 2 years of age (Defined as any of the following: legal blindness, sensorineural deafness requiring hearing aids, moderate or severe cerebral palsy or developmental delay/intellectual impairment (developmental quoti... · newborn infants at risk of neonatal hypoglycaemia
Dextrose gel showed no clear difference in major neurological disability at 2 years of age (Defined as any of… compared with placebo (low certainty).
1 finding from 1 review
Moderate to severe neurodevelopmental outcome at 18 to 24 months№ of participants: 0 (0 RCTs) · preterm infants at risk for bronchopulmonary dysplasia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found